CytoSorbents (CytoSorbents) Additional Paid-In Capital : $305.98 Mil(As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is CytoSorbents Additional Paid-In Capital?

CytoSorbents's quarterly additional paid-in capital increased from Sep. 2023 ($292.15 Mil) to Dec. 2023 ($305.20 Mil) and increased from Dec. 2023 ($305.20 Mil) to Mar. 2024 ($305.98 Mil).

CytoSorbents's annual additional paid-in capital increased from Dec. 2021 ($283.19 Mil) to Dec. 2022 ($287.00 Mil) and increased from Dec. 2022 ($287.00 Mil) to Dec. 2023 ($305.20 Mil).

CytoSorbents Additional Paid-In Capital Historical Data

The historical data trend for CytoSorbents's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoSorbents Additional Paid-In Capital Chart

CytoSorbents Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

191.65

277.53

283.19

287.00

305.20

CytoSorbents Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															288.51	290.20	292.15	305.20	305.98

CytoSorbents Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

CytoSorbents Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of CytoSorbents's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoSorbents (CytoSorbents) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CytoSorbents Corp (NAS:CTSO) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

HQE1:Germany

Address

305 College Road East, Princeton, NJ, USA, 08540

Website

https://www.cytosorbents.com

CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.

Executives

Edward Raymond Jones	director	70 HOGAN LANE, AMBLER PA 19002
Kathleen P. Bloch	officer: Chief Financial Officer	3 PERSHING COURT, NORTH BRUNSWICK NJ 08902
Vincent Capponi	officer: Chief Operating Officer	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Phillip P. Chan	director, officer: President and CEO	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Efthymios Deliargyris	officer: Chief Medical Officer	C/O PLX PHARMA,INC.8285 EL RIO STREET, SUITE 210, HOUSTON TX 77054
Jiny Kim	director	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Alan D. Sobel	director	293 EISENHOWER PARKWAY, LIVINGSTON NJ 07039
Michael G. Bator	director	C/O CYTOSORBENTS CORP., 7 DEER PARK DR., SUITE K, MONMOUTH JUNCTION NJ 08852
Alex D'amico	officer: Chief Financial Officer	10 EAST PASSAIC AVENUE, UNIT C-2, NUTLEY NJ 07110
Al Kraus	director	MEDASORB TECHNOLOGIES, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Eric R. Mortensen	officer: Chief Medical Officer	C/O CYTOSORBENTS CORPORATION, 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852
Njtc Investment Fund, Lp	10 percent owner	1001 BRIGGS ROAD, SUITE 280, MOUNT LAUREL NJ 08054
Robert Shipley	10 percent owner	9 NOBLE ROAD, NOGALES AZ 85621
Ronald Berger	officer: See Remarks	7 DEERPARK DRIVE, STE K, MONMOUTH JUNCTION NJ 08852
Thomas Bocchino	officer: Chief Financial Officer	C/O CYTOSORBENTS CORP., 7 DEER PARK DRIVE, SUITE K, MONMOUTH JUNCTION NJ 08852